KOOS

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Wednesday, March 13, 2024
Knee, Congress, Biologics license application, Patient, ATMP, Research, World Congress, OARSI, European Medicines Agency, WOMAC, Osteoarthritis Research Society International, KOOS, Drug development, Safety, Pain, Vasopressin receptor 2, DVD-Audio, Food, Osteoarthritis, FDA, BLA, Pharmaceutical industry

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

Riverside Health System and Upfront Healthcare Announce Success of Joint Patient Engagement Program for Total Hip and Knee Replacement Journeys

Retrieved on: 
Wednesday, February 7, 2024
Data Management, Practice Management, Physical Therapy, Technology, Managed Care, Health, Health Technology, Other Technology, Hospitals, Surgery, Networks, THR, Knee, Up Front, KOOS, Hip, Patient, RHS, Certification, Riverside Health System, Education, Health care, Associate, TKR, Nursing

The success of the orthopedic care journey program has resulted in RHS scaling Upfront’s patient engagement technology to Riverside Walter Reed Hospital (RWRH).

Key Points: 
  • The success of the orthopedic care journey program has resulted in RHS scaling Upfront’s patient engagement technology to Riverside Walter Reed Hospital (RWRH).
  • Increased patient engagement – 97.5% platform participation with overall engagement and a click-through rate of 85%.
  • Comprehensive patient education is essential for successful joint replacement surgeries, and is also mandatory for the DNV Advanced Hip and Knee Replacement Certification.
  • “Riverside Health System selected Upfront Healthcare’s patient engagement platform for its ability to develop personalized microsites that win patient loyalty as they are guided on their orthopedic care journey.

InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial

Retrieved on: 
Friday, November 3, 2023
FDA, Stem Cells, Pharmaceutical, Surgery, Physical Therapy, Managed Care, General Health, Hospitals, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Medical Supplies, Patient, Insurance, VAS, RT, Syndrome, Ludwig Maximilian University of Munich, Literature, Policy, Treatment, Visual analogue scale, Khaneqah Bala va Pain, Injection, OA, Pain, CSI, Osteoarthritis, KOOS, Evidence-based medicine, Cell, Clinical trial, Guideline, Knee, Emory University, MILES, Total, Knee pain, Gottschalk, Pharmaceutical industry, Medical imaging, InGeneron

InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).

Key Points: 
  • InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).
  • Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
  • At InGeneron, we are dedicated to evidence-based medicine and deeply value our partnerships with respected institutions like Emory University.
  • Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.

American Joint Replacement Registry Releases 10th Annual Report

Retrieved on: 
Friday, November 3, 2023
American Joint Replacement Registry, MSTR, III, Publication, Medicare, American Association of Neurological Surgeons, Nursing, Abdominal ultrasonography, Registry, Fracture, Orthopedic surgery, Paced Auditory Serial Addition Test, Estate (law), KOOS, ASR, TKA, Hip, Growth, Database, SER, COVID-19, Surgeon, AANS, American Academy, Hospital, Annual report, Collection, THA, Shoulder, Patient, Robotics, AAOS, FTR, Medical device, Pharmaceutical industry, BBC, MD

ROSEMONT, Ill., Nov. 3, 2023 /PRNewswire/ -- The American Joint Replacement Registry (AJRR), the cornerstone of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program, published its 2023 Annual Report on hip and knee arthroplasty procedural trends and patient outcomes today. Marking the 10th anniversary edition of the report, the data represents over 3.1 million primary and revision hip and knee arthroplasty procedures performed between 2012 and 2022. This is a 23% growth in procedural cases from the prior report.

Key Points: 
  • ROSEMONT, Ill., Nov. 3, 2023 /PRNewswire/ -- The American Joint Replacement Registry (AJRR), the cornerstone of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program , published its 2023 Annual Report on hip and knee arthroplasty procedural trends and patient outcomes today.
  • Marking the 10th anniversary edition of the report, the data represents over 3.1 million primary and revision hip and knee arthroplasty procedures performed between 2012 and 2022.
  • The American Joint Replacement Registry (AJRR) , the Academy's hip and knee replacement registry, is the cornerstone of the AAOS's Registry Program, and the world's largest national registry of hip and knee joint replacement data by annual procedural count, with more than 3 million procedures contained within its database.
  • Additional registries include the Fracture & Trauma Registry (FTR), the Musculoskeletal Tumor Registry (MsTR), the Shoulder & Elbow Registry (SER), and the American Spine Registry (ASR), a collaborative effort between the American Association of Neurological Surgeons (AANS) and the AAOS.

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Retrieved on: 
Thursday, September 7, 2023
HTN, AE, Lidocaine, OAK, Oxycodone, Aes, Clinical trial, ECG, Capsaicin, Bankruptcy, Female, Pain, Hypertension, SPID, SAE, Patient, Standard of care, WOMAC, KOOS, SAN, OTC, Hydromorphone, BMI, FDA, Therapy, Triamcinolone acetonide, RTX, Safety, Pharmaceutical industry, Birth control

RTX 20mcg and 12.5mcg have been selected as the clinically optimal and minimally effective doses for further phase 2 pivotal or phase 3 trials.

Key Points: 
  • RTX 20mcg and 12.5mcg have been selected as the clinically optimal and minimally effective doses for further phase 2 pivotal or phase 3 trials.
  • SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.
  • A higher proportion of patients responded to treatment with RTX 20mcg than any other treatment group, including Zilretta.
  • The clinical trial confirmed the potential of resiniferatoxin (RTX) in helping patients with moderate to severe osteoarthritis pain for at least 6 months, if not longer.

Digital Care Management Improves MSK Care, Force Therapeutics Report Shows

Retrieved on: 
Tuesday, July 18, 2023
Pros, CMS, ODI, Hip, Shoulder, Centers for Medicare & Medicaid Services, Disability, VBC, Center for Medicare and Medicaid Innovation, Element, ASES, MCID, Pain, Medicare, Hospital, Patient, Collection, Length of stay, KOOS, Force, MSK, BBC, Geisinger Health System, FFS, Therapy, SCB, Mental health, Knee, Medical device, Nursing, Pharmaceutical industry, Health insurance, Birth control

NEW YORK, July 18, 2023 /PRNewswire/ -- Force Therapeutics, the leading musculoskeletal (MSK) digital care management platform, announced today the release of a new report demonstrating that its virtual care management and remote engagement platform resulted in clinically significant improvements in patient-reported outcomes (PROs) including pain, function, mental health, and activities of daily living in MSK patients.

Key Points: 
  • Upcoming CMS incentives require providers to drive high-quality, value-based care through stronger patient engagement and care pathway compliance
    NEW YORK, July 18, 2023 /PRNewswire/ -- Force Therapeutics, the leading musculoskeletal (MSK) digital care management platform, announced today the release of a new report demonstrating that its virtual care management and remote engagement platform resulted in clinically significant improvements in patient-reported outcomes (PROs) including pain, function, mental health, and activities of daily living in MSK patients.
  • 90% of patients reported being "satisfied" or "very satisfied" with their surgical episodes combined with Force Therapeutics' care management plans.
  • "Providers must be prepared for the increasingly rigorous requirements surrounding care quality and outcomes, which necessitate the implementation of holistic digital and remote care solutions," said Bronwyn Spira, CEO and founder, Force Therapeutics.
  • "Without a comprehensive digital care strategy and strong patient engagement, providers will find it difficult to succeed in the rapidly evolving MSK care landscape," said Mark Lieberman, President and co-founder, Force Therapeutics.

STUDY ON PROCHONDRIX OSTEOCHONDRAL ALLOGRAFT PUBLISHED IN THE JOURNAL OF ORTHOPAEDIC SURGERY DEMONSTRATES ENCOURAGING OUTCOMES WHEN USED ON ISOLATED ARTICULAR CARTILAGE DEFECTS

Retrieved on: 
Thursday, June 29, 2023
Surgeon, Quality of life, Allotransplantation, Cartilage, Knee, Research, Short, Journal, Journal of Orthopaedic Surgery and Research, Chondrocyte, Patient, KOOS, Orthopedic surgery, Sport, Costal cartilage, Medical device

CENTENNIAL, Colo., June 29, 2023 /PRNewswire/ -- AlloSource®, a leading innovator and manufacturer of cartilage for joint preservation, today announced the Journal of Orthopaedic Surgery published the study titled " Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the treatment of articular cartilage defects in the knee ."

Key Points: 
  • CENTENNIAL, Colo., June 29, 2023 /PRNewswire/ -- AlloSource®, a leading innovator and manufacturer of cartilage for joint preservation, today announced the Journal of Orthopaedic Surgery published the study titled " Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the treatment of articular cartilage defects in the knee ."
  • This study demonstrated encouraging patient-reported outcomes in the treatment of symptomatic articular cartilage lesions using a laser-etched osteochondral allograft, ProChondrix.
  • "ProChondrix has been a valuable addition to my cartilage restoration treatment options and my patient outcomes have been encouraging," said Dr. Mehta.
  • "The results of this study capture the potential ProChondrix has to help surgeons heal their patients needing articular cartilage repair."

PROCHONDRIX CR, ALLOSOURCE'S NOVEL LASER ETCHED CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFT, SHOWS POSITIVE PATIENT-REPORTED OUTCOMES IN PROSPECTIVE CLINICAL STUDY ON FOCAL ARTICULAR CARTILAGE DEFECTS IN THE KNEE

Retrieved on: 
Wednesday, March 8, 2023
American Academy, Knee, KOOS, Surgeon, Quality of life, Innovation, Patient, IKDC, Cartilage, Sport, New product development, Hospital, Birth control

These patient-reported outcomes showed sustained positive result scores with statistical significance achieved at the 6-, 12-, 24- and 36- months postoperatively.

Key Points: 
  • These patient-reported outcomes showed sustained positive result scores with statistical significance achieved at the 6-, 12-, 24- and 36- months postoperatively.
  • This clinical data continues to tell the story of the positive impact ProChondrix CR can have on patient recovery," said Carolyn Rorick, AlloSource Senior Director Product Development, Innovation and Clinical Affairs.
  • 2 The two-year shelf life helps to alleviate inventory management challenges and provides surgeons with more flexibility for their patients.
  • For additional detail on ProChondrix CR's clinical outcomes visit booth #6627 at the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas March 7-11, 2023 or allosource.org .

New Study Shows High Patient Satisfaction and Outcomes After Outpatient Joint Arthroplasty at Academic Medical Centers

Retrieved on: 
Tuesday, March 7, 2023
TKA, MD, Cone Health Women's Hospital, American Academy, Hip, Approximation error, AMC, Patient, KOOS, AAOS, THA, Abdominal ultrasonography, Academic medical centre, Literature, UKA, Risk, Faculty, Patient satisfaction, TJA, Pros, Pain, Harvard Medical School, William H. Harris (orthopaedic surgeon), Length of stay, Hospital, Observation, United, Academic Medical Center (Amsterdam), Brigham

LAS VEGAS, March 7, 2023 /PRNewswire/ -- In the first study to establish patient satisfaction after outpatient total joint arthroplasty (TJA) in an academic medical center (AMC) setting, patients indicated they were very likely to undergo the outpatient procedure again and had high patient reported outcomes (PROs).

Key Points: 
  • LAS VEGAS, March 7, 2023 /PRNewswire/ -- In the first study to establish patient satisfaction after outpatient total joint arthroplasty (TJA) in an academic medical center (AMC) setting, patients indicated they were very likely to undergo the outpatient procedure again and had high patient reported outcomes (PROs).
  • The study, "Patient Satisfaction and Outcomes following Outpatient Joint Arthroplasty in Academic Medical Centers," presented at the 2023 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, also showed that patients had short discharge times and low readmission rates after outpatient total joint arthroplasty.
  • "Academic medical centers historically haven't done TJAs on a same day basis," said lead author Soham Ghoshal, medical student, Harvard Medical School, Boston.
  • AMCs have the advantage that should a patient need to be admitted for further observation, that transition can easily be done."

Zimmer Biomet Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

Retrieved on: 
Saturday, November 5, 2022
Patient, Hip, UC, Randomized controlled trial, JR, PT, NYSE, Apple Watch, KOOS, Rehabilitation, IPhone, Orthopedic surgery, Association, American Association, Hospital, Medicine, MD

WARSAW, Ind., Nov. 5, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced one-year data from a multicenter, prospective, randomized controlled trial to evaluate the impact of mymobility® with Apple Watch, a first-of-its-kind remote care management platform. The data show that using mymobility with Apple Watch following primary knee arthroplasty, commonly known as knee replacement, can effectively guide rehabilitation, demonstrate similar outcomes to traditional care models, and significantly reduce the number of outpatient physical therapy (PT) visits. In addition, use of mymobility with Apple Watch was associated with significantly fewer surgery-related emergency department (ED) visits, which could translate to lower costs of care*. The data will be presented at a podium session at the 2022 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).

Key Points: 
  • The data will be presented at a podium session at the 2022 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).
  • In the study, these benefits may have contributed to lower utilization of healthcare resources, which can result in cost savings per episode of care."
  • The data presented at the 2022 AAHKS annual meeting evaluated 401 patients who underwent total or partial knee arthroplasty.
  • Patients were randomized to a mymobility with Apple Watchexercise and educational platform group, or a control group who received traditional care.